Department of Health
Fourteen Australian start-up and innovative companies will receive funding and commercialisation support to develop:
- devices that address atrial fibrillation, ocular drug delivery, high-risk coronary artery disease, cardiogenic shock, stroke, and preeclampsia
- drugs or treatments for kidney disease, acute ischaemic stroke, diabetic retinopathy, atherosclerotic cardiovascular disease, type 1 and 2 diabetes, diabetic kidney disease and peripheral arterial disease.
Funding is from the Targeted Translation Research Accelerator program under the MRFF’s Preventive and Public Health Research initiative. Industry will contribute over $17 million in additional funding to these projects.
Read the media release
/Media Release. View in full here.
